Kangstem Biotech

At a glance

Kangstem Biotech filed 30 disclosures in the last 12 months, including 7 insider and 1 5% holder. The most recent key filing was on Apr 3.

Revenue for 2025 was ₩3.6B, down 53.9% on 2024. It made an operating loss of ₩17.7B. Debt was 18% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.4B and operating loss of ₩10.6B.

The 2025 annual report lists 86 employees with an average tenure of 4.4 years and average pay of ₩57.6M, #1090 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩117M each on average. It paid no cash dividend for 2025. 주식회사 세종 and related parties held 19.79% at year end.

From the 2025 annual report

Staff: 86 (36 men, 50 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩4.9B. Directors and auditors: 6, paid ₩703M in total.

No cash dividend was paid for 2025.

Largest shareholder

주식회사 세종 holds 19.79%; with 0 related parties the group holds 19.79% of common shares at year end (from 14.27% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary